Oncogene

ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science

Retrieved on: 
Thursday, February 16, 2023
Biomarker, Mayo Clinic, Prophase, Oncogene, Carcinogenesis, Protein, Molecular biology, Clinical professor, LDT, Biotechnology, HIV disease progression rates, Hyperkinesia, Canadian International Council, MDPI, Cell, Research, International Journal of Molecular Sciences, Translation, Outline of health sciences, Cancer, Esophageal cancer, Proteomics, Growth, Genomics, Western University, Medical imaging, Mittal

The article highlights the current clinical limitations and future molecular innovations of Barrett’s esophagus-related cancer.

Key Points: 
  • The article highlights the current clinical limitations and future molecular innovations of Barrett’s esophagus-related cancer.
  • Dr. Agrawal is the Director of Research & Biotechnology and Professor in Translational Research at Western University of Health Sciences.
  • Dr. Abdo has over a decade of experience researching molecular oncology mechanisms in gastrointestinal diseases and has published dozens of peer-reviewed articles on esophageal cancer.
  • In the coming weeks, we plan to further update our shareholders as to our progress and development timelines for our BE-Smart Esophageal Cancer Test.

Global KRAS Inhibitors Market Report to 2029: Featuring Ascentage Pharma, AstraZeneca, Boehringer Ingelheim and BridgeBio Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Pharmaceutical, Health, FIRST, Mirati Therapeutics, Oncogene, Biology, Diagnosis, Patient, Sale, Adagrasib, Research, Neoplasm, Sotorasib, RAS, KRAS, Lung cancer, Amgen, FDA, Growth, Qiagen, Creativity, NSCLC, Cancer, Pharmaceutical industry

KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for the possible development of novel KRAS inhibitors.

Key Points: 
  • KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for the possible development of novel KRAS inhibitors.
  • The future pipeline of this target looks flourishing as several pharmaceutical companies also plan on bringing novel drug candidates against KRAS.
  • Researchers worldwide have known about KRAS mutations for several years; however, the available therapies against it were proven to be indefinable.
  • It is both interesting and concerning how KRAS mutations play a significant role in the pathogenesis and proliferation of cancer.

RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, February 7, 2023
Vaccine, Messenger, Oncogene, Drug resistance, Therapy, Intellectual property, Annual general meeting, Cancer, Patient, Food, RAS, Investigational New Drug, RNA interference, AACR, Immunization, American Association for Cancer Research

The AACR Annual Meeting will take place April 14–19, 2023 in Orlando, Florida, the United States.

Key Points: 
  • The AACR Annual Meeting will take place April 14–19, 2023 in Orlando, Florida, the United States.
  • RNAimmune is a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines.
  • New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
    RNAimmune will present a pre-clinical study showing the latest progress of mRNA cancer vaccine.
  • The reported Pan RAS mRNA cancer vaccine was designed and screened by RNAimmune, which owns its proprietary independent intellectual property rights.

RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting

Retrieved on: 
Monday, February 6, 2023
Vaccine, Messenger, Oncogene, Drug resistance, Intellectual property, Cancer, Patient, Food, Research, RAS, Investigational New Drug, The Company, AACR, Immunization

GERMANTOWN, Md., Feb. 6, 2023 /PRNewswire/ -- RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that its RNAimmune mRNA cancer vaccine program has been accepted for oral presentation at the AACR Annual Meeting 2023.

Key Points: 
  • GERMANTOWN, Md., Feb. 6, 2023 /PRNewswire/ -- RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that its RNAimmune mRNA cancer vaccine program has been accepted for oral presentation at the AACR Annual Meeting 2023.
  • RNAimmune will present a pre-clinical study showing the most recent mRNA cancer vaccine progress.
  • The reported Pan RAS mRNA cancer vaccine was designed and screened by RNAimmune, which owns its proprietary independent intellectual property rights.
  • Found in 1907, AACR is the first and largest cancer research organization dedicated to fighting against cancer.

In Partnership with Rising Tide Foundation, LUNGevity Issues RFA for $1.5M Lung Cancer Research Grant

Retrieved on: 
Wednesday, January 25, 2023
Caregiver, LOI, MPH, Lung cancer, Oncogene, Lois, Faculty, Research, Cancer, Doctor of Philosophy, RFA, Patient, Neoplasm, History, Pharmaceutical industry

WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- LUNGevity Foundation is pleased to partner with Rising Tide Foundation, a global philanthropic organization based in Switzerland, to issue a Request for Application (RFA) to study how shared mechanisms of resistance can be targeted in oncogene-driven lung cancers.

Key Points: 
  • These targeted therapies have been incredibly impactful and effective for many patients," noted Upal Basu Roy, PhD, MPH, LUNGevity's executive director of research.
  • The Rising Tide/LUNGevity Team Award Program to Target Mechanisms of Resistance aims to fund high-impact research to understand and target these shared resistance mechanisms in oncogene-driven lung adenocarcinoma.
  • "Rising Tide Foundation has a longstanding history of funding innovative, patient-centered clinical research to positively impact the lives of people diagnosed with cancer.
  • We fund high-priority research areas and are thrilled to partner with LUNGevity, the largest philanthropic funder of lung cancer research in the United States.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

Retrieved on: 
Tuesday, February 7, 2023
Netherlands Cancer Institute, Observation, Survival, Drug resistance, Patient, Growth, Oncogene, WEE1, Toxicity, Pharmaceutical industry

PASADENA, CA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) noted that a team of scientists headed by Professor Rene Bernards at the Netherlands Cancer Institute, Amsterdam and member of the Board of Directors of LIXTE reported that in three difficult to treat cancer types, LIXTE’s lead clinical compound, LB-100, combined with an inhibitor of the WEE1 kinase, causes unexpectedly effective cancer cell killing. Most surprisingly, when cancer cells acquire resistance to this combination therapy, they have highly reduced cancer-causing capacity in animal models. This observation indicates that this LB-100 combination therapy can force cells to give up their cancer-causing properties to acquire drug resistance.

Key Points: 
  • Most surprisingly, when cancer cells acquire resistance to this combination therapy, they have highly reduced cancer-causing capacity in animal models.
  • This observation indicates that this LB-100 combination therapy can force cells to give up their cancer-causing properties to acquire drug resistance.
  • Normal cells, which are not in proliferation overdrive in the first place, apparently can tolerate transient overstimulating signaling much better than cancer cells.
  • However, given the safety profile in animal models of LB-100 in combination with WEE1 inhibition, this hypothesis should be readily testable in the clinic.”

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Retrieved on: 
Tuesday, January 17, 2023
Cancer, CRC, Neoplasm, PDAC, Patient, RAS, KRAS, Acquisition, Oncogene, Osteopathic medicine in Canada, Pharmaceutical industry, NSCLC

KRAS G12C, KRAS G12D and KRAS G12V are among the most common KRAS mutations.

Key Points: 
  • KRAS G12C, KRAS G12D and KRAS G12V are among the most common KRAS mutations.
  • With only two approved therapies both targeting only KRAS G12C for locally advanced or metastatic NSCLC, KRAS-driven tumors continue to represent a significant unmet medical need.
  • As previously reported by Biomea, KRAS-mutant NSCLC, CRC, and PDAC cell lines and ex vivo patient specimens were highly sensitive to BMF-219 in preclinical models.
  • The higher levels of activity of BMF-219 were observed among various KRAS-mutant solid tumor cell lines, but not KRAS wild type, suggesting that BMF-219 broadly inhibited mutant KRAS in these tumor models.

Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Retrieved on: 
Thursday, January 5, 2023
Disease, University of Minnesota Medical School, Food, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hope, Death, HSCT, Hurler, Division, Pediatric Blood & Cancer, Growth, Patient, Mortality, Safety, Oncogene, University, FDA, IND, HSC, Diagnosis, Pharmaceutical industry

The company expects to initiate a global registrational trial evaluating the efficacy and safety of OTL-203 compared to standard of care in the second half of 2023.

Key Points: 
  • The company expects to initiate a global registrational trial evaluating the efficacy and safety of OTL-203 compared to standard of care in the second half of 2023.
  • “Based on data from the proof-of-concept trial, treatment with a single administration of OTL-203 has the potential to address a range of multisystemic manifestations of MPS-IH,” said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics.
  • A total of 40 patients with a confirmed diagnosis of MPS-IH who meet the study inclusion criteria will be randomized 1:1 to receive either OTL-203 or allogeneic HSCT.
  • We are encouraged by today's announcement and the hope that a one-time gene therapy could offer this community if approved.”

Tactical Therapeutics, Inc., Developer of CTO Treatments for Glioblastoma, Selected to Present at MedInvest Oncology Investor Conference December 14-15 in New York

Retrieved on: 
Tuesday, December 13, 2022
Therapy, Recurrence, Glioblastoma, TTI, Conference, Veteran, Bevacizumab, Drug discovery, IP, Patient, OS, Oncogene, Temozolomide, Brain, Cancer, Calcium, Calcium signaling, Survival, RNA transfection, Tactic, Radiation, Safety, Mass flow (life sciences), Burn, GBM, Health, Gene, Pharmaceutical industry, Medical device, Phase

Glioblastoma, the brain tumor that killed Senator Ted Kennedy, Beau Biden and Senator John McCain, is still mostly untreatable.

Key Points: 
  • Glioblastoma, the brain tumor that killed Senator Ted Kennedy, Beau Biden and Senator John McCain, is still mostly untreatable.
  • Recent reports suggest veterans of Vietnam, Iraq and Afghanistan wars who were exposed to burn pits later developed GBM.
  • GBM exhibits debilitating neurological symptoms and suicide rates for GBM patients are higher compared to those with other cancers.
  • Tactical Therapeutics, Inc., is a privately funded company that has developed a patented lead therapeutic, CTO, for glioblastoma and other solid cancers.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.